Adult Leukemia Research Center
成人白血病研究中心
基本信息
- 批准号:7681358
- 负责人:
- 金额:$ 14.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-03-22 至 2012-02-28
- 项目状态:已结题
- 来源:
- 关键词:Adoptive ImmunotherapyAllogenicBiometryBone Marrow TransplantationCaringCell TransplantationCell physiologyCellsChronic Myeloid LeukemiaClinicalClinical ResearchDevelopmentDiseaseDisease ProgressionElderlyGastroenterologyGoalsGrantHealthHematologic NeoplasmsHematopoieticHematopoietic NeoplasmsHomologous TransplantationImmunogeneticsImmunotherapyIndividualInternationalLaboratoriesLearningLeftMalignant - descriptorMalignant NeoplasmsMethodsMicrobiologyMolecularNephrologyNumbersPathologyPatientsPreventionProtocols documentationPublic HealthPulmonologyRecurrenceRelapseResearchResearch PersonnelResistanceSafetyStandards of Weights and MeasuresTechniquesTimeTransplant RecipientsTransplantationWorkadult leukemiabasecancer immunotherapydisabilityfollow-upgraft vs host diseaseimprovedinsightleukemiapre-clinical researchprogramstransplant registrytumorvirology
项目摘要
Adult Leukemia Research Center Program Project
The overall goal of this program project is to improve allogeneic hematopoietic cell transplantation (HCT)
as treatment for hematological malignancies. Specifically, we propose laboratory and clinical studies to
increase the safety of transplantation, to enhance the anti-tumor effects of transplantation, to broaden the
availability of transplantation, and to improve our ability to apply transplantation at the appropriate time in the
course of disease. Six individual projects are proposed:
1. Nonmyeloablative Hematopoietic Cell Allotransplants
2. Immunogenetics of Graft-Versus-Host Disease
3. Prevention and Treatment of Graft-Versus-Host Disease
4. Resistance and Relapse of Chronic Myeloid Leukemia
5. Specific Adoptive Immunotherapy of Leukemia
6. Targeting Alloreactivity for Leukemia Eradication
In addition, core support is requested in biostatistics, pathology, microbiology and virology, gastroenterology,
pulmonary medicine and nephrology, cell processing, long-term follow-up, and administration. Our ability to
successfully carry out the proposed work is greatly benefited by: (1) the existence of a large group of
investigators all focused on the general topic of HCT; (2) strong preclinical research programs at our Center
in support of this topic; and (3) the accrual of 450-500 transplant patients onto research protocols each year.
Relevance to Public Health: This Program Project has direct relevance to the more than 18,000 patients
who undergo allogeneic HCT for treatment of hematopoietic malignancies each year. The work proposed
promises to make transplantation safer, more effective, increasingly available and more appropriately
applied. Further, lessons learned from our planned studies will apply to issues of transplant tolerance, the
molecular basis of malignant disease progression, and especially the immunotherapy of cancer.
成人白血病研究中心计划项目
该计划项目的总体目标是改进同种异体造血细胞移植(HCT)
作为血液系统恶性肿瘤的治疗。具体来说,我们建议进行实验室和临床研究
提高移植的安全性,增强移植的抗肿瘤作用,拓宽移植的应用范围
移植的可用性,并提高我们在适当的时间应用移植的能力
病程。提议了六个单独的项目:
1. 非清髓性造血细胞同种异体移植
2. 移植物抗宿主病的免疫遗传学
3. 移植物抗宿主病的预防和治疗
4. 慢性粒细胞白血病的耐药和复发
5. 白血病的特异性过继免疫治疗
6. 针对白血病根除的同种异体反应性
此外,还需要生物统计学、病理学、微生物学和病毒学、胃肠病学、
肺病学和肾病学、细胞处理、长期随访和给药。我们的能力
成功开展拟议工作的好处是:(1)一大群人的存在
研究人员都集中在 HCT 的一般主题上; (2)中心强大的临床前研究项目
支持该主题; (3) 每年有 450-500 名移植患者参与研究方案。
与公共卫生的相关性:该计划项目与超过 18,000 名患者直接相关
每年接受同种异体 HCT 治疗造血系统恶性肿瘤的患者。拟议的工作
承诺使移植更安全、更有效、更容易获得且更适当
应用。此外,从我们计划的研究中吸取的经验教训将适用于移植耐受问题,
恶性疾病进展的分子基础,特别是癌症的免疫治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
FREDERICK APPELBAUM其他文献
FREDERICK APPELBAUM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('FREDERICK APPELBAUM', 18)}}的其他基金
Blood & Marrow Clinical Trials Network- Hutchinson Center as Core Clinical Site
血
- 批准号:
10430215 - 财政年份:2022
- 资助金额:
$ 14.07万 - 项目类别:
Hutchinson Center as Lead Academic Participating Site (U10)
哈钦森中心作为主要学术参与地点 (U10)
- 批准号:
8605625 - 财政年份:2014
- 资助金额:
$ 14.07万 - 项目类别:
Hutchinson Center as Lead Academic Participating Site (U10)
哈钦森中心作为主要学术参与地点 (U10)
- 批准号:
9234504 - 财政年份:2014
- 资助金额:
$ 14.07万 - 项目类别:
Hutchinson Center as Lead Academic Participating Site (U10)
哈钦森中心作为主要学术参与地点 (U10)
- 批准号:
9031739 - 财政年份:2014
- 资助金额:
$ 14.07万 - 项目类别:
Hutchinson Center as Lead Academic Participating Site (U10)
哈钦森中心作为主要学术参与地点 (U10)
- 批准号:
8850832 - 财政年份:2014
- 资助金额:
$ 14.07万 - 项目类别:
相似海外基金
HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
- 批准号:
10039902 - 财政年份:2022
- 资助金额:
$ 14.07万 - 项目类别:
EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
- 批准号:
21K15925 - 财政年份:2021
- 资助金额:
$ 14.07万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
- 批准号:
21K08410 - 财政年份:2021
- 资助金额:
$ 14.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
- 批准号:
20K21672 - 财政年份:2020
- 资助金额:
$ 14.07万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
- 批准号:
18K16395 - 财政年份:2018
- 资助金额:
$ 14.07万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
- 批准号:
17K10951 - 财政年份:2017
- 资助金额:
$ 14.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
- 批准号:
370541 - 财政年份:2017
- 资助金额:
$ 14.07万 - 项目类别:
Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
- 批准号:
16K10863 - 财政年份:2016
- 资助金额:
$ 14.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
- 批准号:
276706135 - 财政年份:2015
- 资助金额:
$ 14.07万 - 项目类别:
Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
- 批准号:
15H04915 - 财政年份:2015
- 资助金额:
$ 14.07万 - 项目类别:
Grant-in-Aid for Scientific Research (B)